DirithromycinCAS# 62013-04-1 |
- MTEP hydrochloride
Catalog No.:BCC1780
CAS No.:1186195-60-7
- mGlu2 agonist
Catalog No.:BCC1745
CAS No.:1311385-32-6
- LY341495
Catalog No.:BCC1724
CAS No.:201943-63-7
- MPEP Hydrochloride
Catalog No.:BCC1777
CAS No.:219911-35-0
- CPPHA
Catalog No.:BCC1501
CAS No.:693288-97-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 62013-04-1 | SDF | Download SDF |
| PubChem ID | 5464388 | Appearance | Powder |
| Formula | C42H78N2O14 | M.Wt | 835.07 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | LY237216 | ||
| Solubility | Ethanol : ≥ 50 mg/mL (59.88 mM) DMSO : 33.33 mg/mL (39.91 mM; Need ultrasonic) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (1S,2R,4R,5R,6S,7S,8R,11R,12R,15R,17S)-5-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-11-ethyl-4,12-dihydroxy-7-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-15-(2-methoxyethoxymethyl)-2,4,6,8,12,17-hexamethyl-10,14-dioxa-16-azabicyclo[11.3.1]heptadecan-9-one | ||
| SMILES | CCC1C(C2C(C(C(CC(C(C(C(C(C(=O)O1)C)OC3CC(C(C(O3)C)O)(C)OC)C)OC4C(C(CC(O4)C)N(C)C)O)(C)O)C)NC(O2)COCCOC)C)(C)O | ||
| Standard InChIKey | WLOHNSSYAXHWNR-GETPLZSYSA-N | ||
| Standard InChI | InChI=1S/C42H78N2O14/c1-15-29-42(10,49)37-24(4)32(43-30(56-37)21-52-17-16-50-13)22(2)19-40(8,48)36(58-39-33(45)28(44(11)12)18-23(3)53-39)25(5)34(26(6)38(47)55-29)57-31-20-41(9,51-14)35(46)27(7)54-31/h22-37,39,43,45-46,48-49H,15-21H2,1-14H3/t22-,23-,24+,25+,26-,27+,28+,29-,30-,31+,32+,33-,34+,35+,36-,37?,39+,40-,41-,42-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Dirithromycin(LY 237216) is a macrolide glycopeptide antibiotic by binding to the 50S subunit of the 70S bacterial ribosome to inhibit the translocation of peptides.
Target: Antibacterial
Dirithromycin is a new macrolide with a spectrum and degree of in vitro antimicrobial activity similar to that of erythromycin. Compared with erythromycin, dirithromycin has a long elimination half-life enabling once-daily administration, and it also achieves a greater cellular:extracellular concentration ratio and higher concentration in some tissues. Multicentre double-blind clinical trials have shown dirithromycin to be similar in efficacy to erythromycin in the treatment of uncomplicated bacterial infections of the respiratory tract and of skin and soft tissues [1]. Dirithromycin offers some attractive pharmacokinetic properties. The long elimination half-life of dirithromycin allows once-daily dosing and higher and more prolonged tissue concentrations than are achievable with erythromycin. The spectrum of activity, adverse effect profile, clinical efficacy, and bacteriologic eradication rate of dirithromycin may be similar to those of erythromycin [2, 3]. References: | |||||
Dirithromycin Dilution Calculator
Dirithromycin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.1975 mL | 5.9875 mL | 11.975 mL | 23.9501 mL | 29.9376 mL |
| 5 mM | 0.2395 mL | 1.1975 mL | 2.395 mL | 4.79 mL | 5.9875 mL |
| 10 mM | 0.1198 mL | 0.5988 mL | 1.1975 mL | 2.395 mL | 2.9938 mL |
| 50 mM | 0.024 mL | 0.1198 mL | 0.2395 mL | 0.479 mL | 0.5988 mL |
| 100 mM | 0.012 mL | 0.0599 mL | 0.1198 mL | 0.2395 mL | 0.2994 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Dirithromycin is a macrolide glycopeptide antibiotic by binding to the 50S subunit of the 70S bacterial ribosome to inhibit the translocation of peptides.
- CCG-63808
Catalog No.:BCC1461
CAS No.:620113-73-7
- CCG-63802
Catalog No.:BCC1460
CAS No.:620112-78-9
- Senkyunolide A
Catalog No.:BCN6351
CAS No.:62006-39-7
- 4,4'-Methylenediphenol
Catalog No.:BCN2690
CAS No.:620-92-8
- Hyoscyamine sulfate hydrate
Catalog No.:BCN2846
CAS No.:620-61-1
- Tribenzylamine
Catalog No.:BCN1817
CAS No.:620-40-6
- 5-Methyl-2-furaldehyde
Catalog No.:BCN3801
CAS No.:620-02-0
- Diphemanil Methylsulfate
Catalog No.:BCC3767
CAS No.:62-97-5
- Nandrolone phenylpropionate
Catalog No.:BCC9089
CAS No.:62-90-8
- Cevadine acetate
Catalog No.:BCC8144
CAS No.:63982-55-8
- H-Aib-OH
Catalog No.:BCC3207
CAS No.:62-57-7
- Lipoic acid
Catalog No.:BCN5980
CAS No.:62-46-4
- p-Menthane-1,2,8-triol
Catalog No.:BCN4148
CAS No.:62014-81-7
- Helichrysetin
Catalog No.:BCN4149
CAS No.:62014-87-3
- Bulgarsenine
Catalog No.:BCN2065
CAS No.:62018-77-3
- Cyclobenzaprine HCl
Catalog No.:BCC6496
CAS No.:6202-23-9
- Juncusol
Catalog No.:BCN2926
CAS No.:62023-90-9
- Ginsenoside F2
Catalog No.:BCN1245
CAS No.:62025-49-4
- Ginsenoside F3
Catalog No.:BCN1077
CAS No.:62025-50-7
- 4-(Dimethylamino)cinnamaldehyde
Catalog No.:BCN4968
CAS No.:6203-18-5
- Onitisin 2'-O-glucoside
Catalog No.:BCN4150
CAS No.:62043-53-2
- Hydroxycitric acid
Catalog No.:BCN2912
CAS No.:6205-14-7
- Nudiposide
Catalog No.:BCN7437
CAS No.:62058-46-2
- Heliotrine N-oxide
Catalog No.:BCN1983
CAS No.:6209-65-0
Structural Correspondence of the Oriented Attachment Growth Mechanism of Crystals of the Pharmaceutical Dirithromycin.[Pubmed:26632998]
Langmuir. 2015 Dec 29;31(51):13802-12.
The oriented attachment (OA) mechanism is promising for designing novel nanomaterials, yet an intensive understanding of the relationship between the crystal structure and attachment orientation is still lacking. In this work, we report layered hexagonal crystals of the pharmaceutical Dirithromycin (DIR) containing multiple layers fabricated via a solvothermal method for a certain period of time at 40 degrees C. These elongated hexagonal crystals experience an OA that is preferentially on the face (001) of the initial crystals to assemble the final crystals into layered stacks. Through agreement with molecular modeling calculations, we predicted the final crystal growth morphology and confirmed the favored attachment surface based on the energy change DeltaE following an OA event. These simulation results at the molecular level yielded good agreement with the crystal growth experiments. This study demonstrates the critical importance of combining experiments with a computational approach to understand the intrinsic molecular details of the OA growth mechanism of other compounds and to design nanomaterials with a desirable morphology and physical and chemical properties.
Evaluation of Possible Genotoxic Activity of Dirithromycin in Cultured Human Lymphocytes.[Pubmed:26576152]
J Toxicol. 2015;2015:535490.
Dirithromycin antibiotic is a 14-membered lactone ring macrolide and is widely used in medicine to treat many different types of bacterial infections. In the present study, the possible genotoxicity of Dirithromycin was evaluated in cultured human lymphocytes by using sister chromatid exchanges (SCEs), chromosome aberration (CA), and micronucleus (MN) tests and also cell proliferation kinetics such as mitotic index (MI), replication index (RI), and nuclear division index (NDI) were analyzed for cytotoxicity. Cell cultures were treated with four different concentrations of Dirithromycin (37.75, 67.50, 125, and 250 microg/mL) for 24 and 48 h periods. Dirithromycin significantly induced SCE and MN frequency at all concentrations in both 24 and 48 h treated cells. In addition, CA level has been markedly increased in the cells treated with almost all concentrations of Dirithromycin for 24 (except 37.75 microg/mL) and 48 h treatment periods as compared to control. However, MI, RI, and NDI values were not affected by the Dirithromycin treatment (p > 0.05). The results of this study indicated that Dirithromycin treatment caused genetic damage by increasing the level of cytogenetic endpoints, suggesting its genotoxic and mutagenic action on human lymphocytes in vitro.
Quantitative analysis of erythromycylamine in human plasma by liquid chromatography-tandem mass spectrometry and its application in a bioequivalence study of dirithromycin enteric-coated tablets with a special focus on the fragmentation pattern and carryover effect.[Pubmed:24424301]
J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Feb 1;947-948:156-63.
A liquid chromatography-tandem mass spectrometry method was developed and validated for the quantification of erythromycylamine, which is the predominant active metabolite of Dirithromycin in human plasma. After solid-phase extraction, the analyte and internal standard (IS) were separated by using an isocratic mobile phase consisting of 20 mM ammonium acetate (pH 3.9, adjusted with formic acid)-acetonitrile (75:25, v/v) on a Phenyl-Hexyl column (150 x 2.1 mm, 3 mum) and then analyzed in positive ion mode under electrospray ionization. Azithromycin was selected as the IS because it has the most similar mass spectrometric and chromatographic behaviors to the analyte. The respective multiple reaction monitoring (MRM) transitions, m/z 368.5>83.2 for erythromycylamine and m/z 375.4>115.2 for IS were chosen to achieve high sensitivity and selectivity in determination. A more acidic mobile phase (pH 3.9) than those of previous reports and a special needle wash (ethylene glycol-acetonitrile-water, 50:30:20, v/v/v, adjusted to pH 3.9 using formic acid) were used to eliminate the carryover effects of the two macrolides. The method exhibited a linear dynamic range of 0.5-440.0 ng/mL for erythromycylamine in human plasma (r=0.9999). The lower limit of quantification (LLOQ) and limit of detection (LOD) were 0.5 and 0.05 ng/mL, respectively. The mean extraction recoveries were higher than 94.0% for the analyte and IS. The intra- and inter-day precisions ranged from 1.4 to 5.4% and from 1.6 to 4.0%, respectively. The accuracy varied between 91.2 and 101.2%. The established method was successfully applied to analyze the human plasma samples from 24 healthy subjects in a bioequivalence study of two Dirithromycin enteric-coated formulations.
Development and validation of an improved liquid chromatographic method for the analysis of dirithromycin.[Pubmed:18970882]
Talanta. 2006 Dec 15;70(5):1064-72.
The official method for the determination of Dirithromycin and related substances in the European Pharmacopoeia (Ph. Eur.) and in the United States Pharmacopeia (USP) is an isocratic liquid chromatographic (LC) method using an ODS column. With this method, the separation of the main component Dirithromycin from its epimer is not complete. Moreover, this method suffers sometimes from drift of the baseline and from subsequent quantitation problems. The required resolution is not easy to obtain. Using an adapted method derived from the one prescribed in the pharmacopoeias, the selectivity of a set of more than 40 reversed-phase columns towards Dirithromycin components was investigated. The selection of the most suitable column was achieved by the chromatographic response function (CRF) approach. Several changes were introduced to the method in order to improve the separation and to overcome the baseline drift problem. The resulting method uses a Zorbax Extend column maintained at 30 degrees C and a mobile phase containing acetonitrile, methanol, 2-propanol, water and a phosphate buffer at pH 7.5. The method allows a good separation of Dirithromycin components, which is much better than that obtained with the existing methods. Several impurities of unknown identity are also separated. The method shows good repeatability, linearity and sensitivity, and it is robust. In addition, it proved to be applicable to a wide number of C18 reversed-phase columns.
